BioCryst Pharmaceuticals, Inc.
BCRX
$7.96
$0.111.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.90M | 5.09M | 32.00K | -26.80M | -14.03M |
| Total Depreciation and Amortization | 335.00K | 329.00K | 331.00K | 2.08M | 311.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.76M | 33.51M | 34.25M | 30.84M | 31.10M |
| Change in Net Operating Assets | -1.37M | 2.38M | -62.13M | -11.33M | -9.13M |
| Cash from Operations | 41.62M | 41.30M | -27.52M | -5.21M | 8.25M |
| Capital Expenditure | -1.34M | -179.00K | -143.00K | -675.00K | -59.00K |
| Sale of Property, Plant, and Equipment | 550.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.37M | 29.31M | 27.24M | 18.47M | 8.55M |
| Cash from Investing | 13.57M | 29.13M | 27.10M | 17.80M | 8.49M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -60.85M | -76.25M | -516.00K | -356.00K | -556.00K |
| Issuance of Common Stock | 2.67M | 3.43M | 2.40M | -- | 2.09M |
| Repurchase of Common Stock | -- | -- | -- | -581.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -628.00K | -866.00K | -1.35M | -3.08M | -261.00K |
| Cash from Financing | -58.81M | -73.69M | 529.00K | -4.02M | 1.27M |
| Foreign Exchange rate Adjustments | -468.00K | 1.36M | 451.00K | -1.30M | 851.00K |
| Miscellaneous Cash Flow Adjustments | 218.00K | -15.06M | -- | -- | -- |
| Net Change in Cash | -3.87M | -16.96M | 558.00K | 7.26M | 18.86M |